KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $3.9 billion.

  • Regeneron Pharmaceuticals' Total Current Liabilities rose 20.87% to $4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 20.87%. This contributed to the annual value of $3.9 billion for FY2024, which is 15.22% up from last year.
  • Regeneron Pharmaceuticals' Total Current Liabilities amounted to $3.9 billion in FY2024, which was up 15.22% from $3.4 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Total Current Liabilities peaked at $3.9 billion during FY2024, and registered a low of $2.7 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Total Current Liabilities value was $3.4 billion (recorded in 2023), while the average stood at $3.5 billion.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 45.79% in 2021, then dropped by 20.12% in 2022.
  • Regeneron Pharmaceuticals' Total Current Liabilities (Yearly) stood at $2.7 billion in 2020, then surged by 45.79% to $3.9 billion in 2021, then fell by 20.12% to $3.1 billion in 2022, then grew by 8.98% to $3.4 billion in 2023, then increased by 15.22% to $3.9 billion in 2024.